Larimar Therapeutics (LRMR) Leerink Global Healthcare Conference 2026 summary

Recent accomplishments and regulatory progress

• Achieved Breakthrough Therapy designation following positive regulatory meetings, with clinical data on mFARS, activities of daily living, Nine-Hole Peg Test, and fatigue scale supporting the application.

• Regulatory agencies agreed to use frataxin as a novel surrogate endpoint, with safety and benefit-risk assessment to be reviewed based on upcoming data cut in Q2.

• FDA moved away from requiring a fixed minimum safety database, opting for a holistic review of safety and efficacy.

• Modified dosing regimen introduced to mitigate allergic reactions, with short-term data to be included in the next data package.

• Ongoing efforts to correlate frataxin levels with clinical outcomes, with additional analyses planned for the next data submission.

Clinical development and trial design

• Global Phase III trial protocol reviewed by both FDA and EMA, with U.S. sites prioritized for early initiation and enrollment starting in Q2.

• Trial includes ambulatory patients aged 12–40, with plans to amend protocol to include children as young as two years old per EMA request.

• Primary outcome differs by region: mFARS in Europe and upright stability in the U.S., reflecting regulatory preferences.

• Enrollment expected to take 12–18 months, with 18 months of dosing and a total readout timeframe of approximately 3–3.5 years.

• Interim analysis planned for sample size adjustment and efficacy review.

Safety, efficacy, and patient population insights

• Most common adverse event is mild to moderate injection site reactions, which decrease over time; anaphylaxis linked to drug interruption and re-initiation.

• Adolescents and children show similar tolerability to adults, with dosing adjusted by weight and capped at 50 mg.

• Substantial adolescent data will be available for regulatory review, with protocol amendments planned for younger children as more safety data is collected.

• Frataxin measurement uses a validated ligand binding LC-MS/MS assay, confirmed across multiple tissues and species.